2,4-thiazolidinedione has been researched along with Alloxan Diabetes in 29 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Type 2 diabetes is the most common cause of chronic renal failure worldwide." | 2.44 | Antiproteinuric and anti-inflammatory effects of thiazolidinedione. ( Li, PK; Szeto, CC, 2008) |
| "Insulin resistance is a characteristic feature of type II diabetes as well as obesity." | 2.41 | [Discovery and development of a new insulin sensitizing agent, pioglitazone]. ( Fujita, T; Ikeda, H; Kawamatsu, Y; Meguro, K; Sohda, T, 2002) |
| "01) even at a dosage of 0." | 1.31 | Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives. ( Imamiya, E; Imoto, H; Kimura, H; Momose, Y; Sohda, T; Sugiyama, Y, 2002) |
| "Troglitazone was able to prevent not only diabetic glomerular hyperfiltration and albuminuria, but an increase in mRNA expression of extracellular matrix proteins and transforming growth factor-beta1 in glomeruli of diabetic rats, without changing blood glucose levels." | 1.31 | Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. ( Haneda, M; Isshiki, K; Kikkawa, R; Koya, D; Maeda, S; Sugimoto, T, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (31.03) | 29.6817 |
| 2010's | 14 (48.28) | 24.3611 |
| 2020's | 6 (20.69) | 2.80 |
| Authors | Studies |
|---|---|
| Angajala, G | 1 |
| Aruna, V | 1 |
| Pavan, P | 1 |
| Guruprasad Reddy, P | 1 |
| Sameeh, MY | 1 |
| Khowdiary, MM | 1 |
| Nassar, HS | 1 |
| Abdelall, MM | 1 |
| Amer, HH | 1 |
| Hamed, A | 1 |
| Elhenawy, AA | 1 |
| Amin, S | 1 |
| Sheikh, KA | 1 |
| Iqubal, A | 1 |
| Ahmed Khan, M | 1 |
| Shaquiquzzaman, M | 2 |
| Tasneem, S | 1 |
| Khanna, S | 1 |
| Najmi, AK | 1 |
| Akhter, M | 1 |
| Haque, A | 2 |
| Anwer, T | 1 |
| Mumtaz Alam, M | 1 |
| Iqbal, S | 1 |
| Jabeen, F | 1 |
| Kahwa, I | 1 |
| Omara, T | 1 |
| Najmi, A | 1 |
| Alam, MS | 4 |
| Thangavel, N | 1 |
| Taha, MME | 1 |
| Meraya, AM | 1 |
| Albratty, M | 1 |
| Alhazmi, HA | 1 |
| Ahsan, W | 1 |
| Azam, F | 1 |
| Naim, MJ | 2 |
| Alam, MJ | 2 |
| Nawaz, F | 1 |
| Naidu, VGM | 2 |
| Aaghaz, S | 1 |
| Sahu, M | 1 |
| Siddiqui, N | 1 |
| Alam, O | 2 |
| Yasmin, S | 1 |
| Capone, F | 1 |
| Laghezza, A | 1 |
| Piaz, FD | 1 |
| Loiodice, F | 1 |
| Vijayan, V | 1 |
| Devadasan, V | 1 |
| Mondal, SK | 1 |
| Atlı, Ö | 1 |
| Baysal, M | 1 |
| Pattnaik, AK | 1 |
| Jayaprakash, V | 1 |
| Lavecchia, A | 1 |
| Alam, MM | 4 |
| Ranjan Srivastava, A | 1 |
| Bhatia, R | 1 |
| Chawla, P | 1 |
| Yang, SC | 1 |
| Tseng, HL | 1 |
| Shieh, KR | 1 |
| Song, YM | 1 |
| Hsu, HY | 1 |
| Chen, MD | 1 |
| Ahmadi, A | 1 |
| Khalili, M | 1 |
| Sohrabi, L | 1 |
| Delzendeh, N | 1 |
| Nahri-Niknafs, B | 1 |
| Ansari, F | 1 |
| Mohammed Iqbal, AK | 1 |
| Khan, AY | 1 |
| Kalashetti, MB | 1 |
| Belavagi, NS | 1 |
| Gong, YD | 1 |
| Khazi, IA | 1 |
| Imoto, H | 1 |
| Imamiya, E | 1 |
| Momose, Y | 1 |
| Sugiyama, Y | 1 |
| Kimura, H | 1 |
| Sohda, T | 2 |
| Kawamatsu, Y | 1 |
| Fujita, T | 1 |
| Meguro, K | 1 |
| Ikeda, H | 1 |
| Kim, BY | 1 |
| Ahn, JB | 1 |
| Lee, HW | 1 |
| Kang, SK | 1 |
| Lee, JH | 1 |
| Shin, JS | 1 |
| Ahn, SK | 1 |
| Hong, CI | 1 |
| Yoon, SS | 1 |
| Ohga, S | 1 |
| Shikata, K | 1 |
| Yozai, K | 1 |
| Okada, S | 1 |
| Ogawa, D | 1 |
| Usui, H | 1 |
| Wada, J | 1 |
| Shikata, Y | 1 |
| Makino, H | 1 |
| Szeto, CC | 1 |
| Li, PK | 1 |
| Kanoh, Y | 1 |
| Bandyopadhyay, G | 1 |
| Sajan, MP | 1 |
| Standaert, ML | 1 |
| Farese, RV | 1 |
| Isshiki, K | 1 |
| Haneda, M | 1 |
| Koya, D | 1 |
| Maeda, S | 1 |
| Sugimoto, T | 1 |
| Kikkawa, R | 1 |
| Suzuki, A | 1 |
| Yasuno, T | 1 |
| Kojo, H | 1 |
| Hirosumi, J | 1 |
| Mutoh, S | 1 |
| Notsu, Y | 1 |
| Berger, J | 1 |
| Tanen, M | 1 |
| Elbrecht, A | 1 |
| Hermanowski-Vosatka, A | 1 |
| Moller, DE | 1 |
| Wright, SD | 1 |
| Thieringer, R | 1 |
| Gupta, S | 1 |
| Baweja, GS | 1 |
| Singh, S | 1 |
| Irani, M | 1 |
| Singh, R | 1 |
| Asati, V | 1 |
| Hidalgo-Figueroa, S | 2 |
| Estrada-Soto, S | 2 |
| Ramírez-Espinosa, JJ | 2 |
| Paoli, P | 1 |
| Lori, G | 1 |
| León-Rivera, I | 1 |
| Navarrete-Vázquez, G | 2 |
| Nazreen, S | 3 |
| Hamid, H | 3 |
| Yar, MS | 2 |
| Dhulap, A | 3 |
| Alam, P | 3 |
| Pasha, MA | 3 |
| Bano, S | 3 |
| Haider, S | 3 |
| Kharbanda, C | 3 |
| Ali, Y | 3 |
| Pillai, KK | 2 |
| Shafi, S | 1 |
| Shahar Yar, M | 1 |
| Pillai, K | 1 |
| Avupati, VR | 1 |
| Yejella, RP | 1 |
| Akula, A | 1 |
| Guntuku, GS | 1 |
| Doddi, BR | 1 |
| Vutla, VR | 1 |
| Anagani, SR | 1 |
| Adimulam, LS | 1 |
| Vyricharla, AK | 1 |
| Almanza-Pérez, JC | 1 |
| Román-Ramos, R | 1 |
| Alarcón-Aguilar, FJ | 1 |
| Hernández-Rosado, JV | 1 |
| Moreno-Díaz, H | 1 |
| Díaz-Coutiño, D | 1 |
2 reviews available for 2,4-thiazolidinedione and Alloxan Diabetes
| Article | Year |
|---|---|
[Discovery and development of a new insulin sensitizing agent, pioglitazone].
Topics: Animals; Clinical Trials as Topic; Clofibrate; Diabetes Mellitus; Diabetes Mellitus, Experimental; D | 2002 |
Antiproteinuric and anti-inflammatory effects of thiazolidinedione.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; In | 2008 |
27 other studies available for 2,4-thiazolidinedione and Alloxan Diabetes
| Article | Year |
|---|---|
Biocatalytic one pot three component approach: Facile synthesis, characterization, molecular modelling and hypoglycemic studies of new thiazolidinedione festooned quinoline analogues catalyzed by alkaline protease from Aspergillus niger.
Topics: alpha-Amylases; alpha-Glucosidases; Animals; Aspergillus niger; Bacterial Proteins; Biocatalysis; Di | 2022 |
Thiazolidinedione Derivatives: In Silico, In Vitro, In Vivo, Antioxidant and Anti-Diabetic Evaluation.
Topics: alpha-Amylases; Animals; Diabetes Mellitus, Experimental; Free Radical Scavengers; Molecular Docking | 2022 |
Synthesis, in-Silico studies and biological evaluation of pyrimidine based thiazolidinedione derivatives as potential anti-diabetic agent.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Pyrimidines; Rats; Thi | 2023 |
Suberosin Alleviates Thiazolidinedione-Induced Cardiomyopathy in Diabetic Rats by Inhibiting Ferroptosis via Modulation of ACSL4-LPCAT3 and PI3K-AKT Signaling Pathways.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Animals; Cardiomyopathies; Coumarins; Diabetes Mellit | 2023 |
Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-γ agonists.
Topics: Animals; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Ligands; Mice; Molecular Docking Simu | 2023 |
Synthesis, molecular docking and anti-diabetic evaluation of 2,4-thiazolidinedione based amide derivatives.
Topics: Amides; Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Hypoglycemic Agent | 2017 |
Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes.
Topics: Animals; Benzylidene Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease | 2017 |
Synthesis, docking, in vitro and in vivo antidiabetic activity of pyrazole-based 2,4-thiazolidinedione derivatives as PPAR-γ modulators.
Topics: 3T3-L1 Cells; Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Dose-Response Relationship, | 2018 |
Synthesis, biological evaluation and molecular docking studies of novel 3,5-disubstituted 2,4-thiazolidinediones derivatives.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Binding Sites; Blood Glucose; Diabetes Mellitus, Ex | 2019 |
Circadian-clock system in mouse liver affected by insulin resistance.
Topics: Animals; Blood Glucose; Body Weight; Circadian Clocks; Circadian Rhythm; Diabetes Mellitus, Experime | 2013 |
Low dietary zinc intake attenuates the efficacy of 2,4-thiazolidinedione on reducing hyperglycemia in db/db mice (Short communication).
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Hyperglycemia; Hypoglycemic Agents; Mice; M | 2015 |
Synthesis and Evaluation of the Hypoglycemic and Hypolipidemic Activity of Sulfonamide-benzothiazole Derivatives of Benzylidene-2,4- thiazolidnedione.
Topics: Animals; Benzothiazoles; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Molecular Structure; | 2017 |
Synthesis, hypoglycemic and hypolipidemic activities of novel thiazolidinedione derivatives containing thiazole/triazole/oxadiazole ring.
Topics: Animals; Chemistry Techniques, Synthetic; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Hypo | 2012 |
Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives.
Topics: Acetic Acid; Animals; Diabetes Mellitus, Experimental; Female; Humans; Hypoglycemic Agents; Imino Ac | 2002 |
Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione.
Topics: 3T3-L1 Cells; Animals; Blood Glucose; Cell Division; Cells, Cultured; Diabetes Mellitus, Experimenta | 2004 |
Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.
Topics: Anilides; Animals; Anti-Inflammatory Agents; Cells, Cultured; Collagen Type IV; Diabetes Mellitus, E | 2007 |
Thiazolidinedione treatment enhances insulin effects on protein kinase C-zeta /lambda activation and glucose transport in adipocytes of nondiabetic and Goto-Kakizaki type II diabetic rats.
Topics: Adipocytes; Animals; Biological Transport; Diabetes Mellitus, Experimental; Enzyme Activation; Gluco | 2000 |
Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats.
Topics: Albuminuria; Animals; Chromans; Diabetes Mellitus, Experimental; Diglycerides; Extracellular Matrix | 2000 |
Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus, Experimental; Female; | 2000 |
Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3 Cells; Adipocytes; Animals; Cycloheximide; Diabetes | 2001 |
Integrated fragment-based drug design and virtual screening techniques for exploring the antidiabetic potential of thiazolidine-2,4-diones: Design, synthesis and in vivo studies.
Topics: Animals; Diabetes Mellitus, Experimental; Drug Design; Hypoglycemic Agents; Mice; Molecular Docking | 2023 |
Synthesis and evaluation of thiazolidine-2,4-dione/benzazole derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B): Antihyperglycemic activity with molecular docking study.
Topics: Animals; Computer Simulation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Respo | 2018 |
Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Gene Expression Reg | 2014 |
Design, synthesis, in silico molecular docking and biological evaluation of novel oxadiazole based thiazolidine-2,4-diones bis-heterocycles as PPAR-γ agonists.
Topics: Animals; Blood Glucose; Computer Simulation; Diabetes Mellitus, Experimental; Drug Design; Female; G | 2014 |
Design, Synthesis, and Biological Evaluation of Thiazolidine-2,4-dione Conjugates as PPAR-γ Agonists.
Topics: 3T3-L1 Cells; Animals; Binding Sites; Blood Glucose; Diabetes Mellitus, Experimental; Drug Design; F | 2015 |
Synthesis, characterization and biological evaluation of some novel 2,4-thiazolidinediones as potential cytotoxic, antimicrobial and antihyperglycemic agents.
Topics: Animals; Anti-Infective Agents; Artemia; Bacteria; Bacterial Infections; Blood Glucose; Diabetes Mel | 2012 |
Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
Topics: 3T3-L1 Cells; Animals; Barbiturates; Binding Sites; Blood Glucose; Catalytic Domain; Diabetes Mellit | 2013 |